NCT02421172 - Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 13, 2015

Primary Completion Date

November 23, 2016

Study Completion Date

November 23, 2016

Conditions

Hidradenitis Suppurativa (Acne Inversa)

Interventions

BIOLOGICAL

CJM112

CJM112 Fully human IgG1 monoclonal antibody

DRUG

Placebo

Trial Locations (16)

4000

Novartis Investigative Site, Roskilde

10098

Novartis Investigative Site, Berlin

20850

Novartis Investigative Site, Rockville

30342

Novartis Investigative Site, Atlanta

32174

Novartis Investigative Site, Ormond Beach

33609

Novartis Investigative Site, Tampa

37215

Novartis Investigative Site, Nashville

44791

Novartis Investigative Site, Bochum

46256

Novartis Investigative Site, Indianapolis

68144

Novartis Investigative Site, Omaha

90045

Novartis Investigative Site, Los Angeles

02114

Novartis Investigative Site, Boston

Unknown

Novartis Investigative Site, Groningen

Novartis Investigative Site, Basel

3015 CE

Novartis Investigative Site, Rotterdam

CH-8091

Novartis Investigative Site, Zurich